HC Wainwright set a $3.00 price target on Lipocine (NASDAQ:LPCN) in a report issued on Friday, January 12th, Marketbeat Ratings reports. The firm currently has a buy rating on the specialty pharmaceutical company’s stock.
Other equities analysts also recently issued research reports about the company. Canaccord Genuity reiterated a hold rating and set a $2.00 price target (down previously from $11.00) on shares of Lipocine in a research report on Tuesday, January 9th. Ladenburg Thalmann Financial Services reiterated a buy rating and set a $11.00 price target on shares of Lipocine in a research report on Thursday, January 11th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the stock. The stock currently has an average rating of Hold and an average target price of $13.50.
Shares of Lipocine (LPCN) traded down $0.10 during mid-day trading on Friday, reaching $1.23. The company’s stock had a trading volume of 651,836 shares, compared to its average volume of 1,095,823. The stock has a market capitalization of $26.07, a P/E ratio of -1.28 and a beta of -0.51. Lipocine has a 52 week low of $1.20 and a 52 week high of $5.33.
Lipocine (NASDAQ:LPCN) last issued its quarterly earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.05. research analysts forecast that Lipocine will post -1.04 EPS for the current fiscal year.
Institutional investors have recently made changes to their positions in the business. Goldman Sachs Group Inc. acquired a new position in shares of Lipocine during the second quarter valued at approximately $300,000. Federated Investors Inc. PA raised its holdings in shares of Lipocine by 9.2% during the second quarter. Federated Investors Inc. PA now owns 88,083 shares of the specialty pharmaceutical company’s stock valued at $354,000 after acquiring an additional 7,429 shares during the last quarter. P.A.W. Capital Corp acquired a new position in shares of Lipocine during the third quarter valued at approximately $397,000. Ameriprise Financial Inc. raised its holdings in shares of Lipocine by 18.2% during the second quarter. Ameriprise Financial Inc. now owns 155,600 shares of the specialty pharmaceutical company’s stock valued at $626,000 after acquiring an additional 24,000 shares during the last quarter. Finally, Vanguard Group Inc. raised its holdings in shares of Lipocine by 39.7% during the second quarter. Vanguard Group Inc. now owns 546,027 shares of the specialty pharmaceutical company’s stock valued at $2,195,000 after acquiring an additional 155,110 shares during the last quarter. 22.12% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: “Lipocine (NASDAQ:LPCN) PT Set at $3.00 by HC Wainwright” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/05/lipocine-lpcn-given-a-3-00-price-target-by-hc-wainwright-analysts.html.
Lipocine Company Profile
Lipocine Inc is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs.
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.